Cipla, Nilotinib Recall, Anti-Cancer Drug, USFDA, Pharma Industry

Cipla’s US Subsidiary Recalls Over 400 Cartons of Anti-Cancer Drug: What It Means for Patients and the Pharma Industry

Cipla USA has recalled over 400 cartons of Nilotinib, a generic anti-cancer drug for CML, due to minor manufacturing specs issues. This Class III recall poses no health risks but highlights quality controls in pharma. Explore implications for patients, Cipla’s stock, and the Indian generics industry in this detailed breakdown. Stay informed on USFDA updates for global drug safety.